THCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
THCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, THC Therapeutics's enterprise value is $0.85 Mil. THC Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jul. 2023 was $0.00 Mil. Therefore, THC Therapeutics's EV-to-Revenue for today is .
The historical rank and industry rank for THC Therapeutics's EV-to-Revenue or its related term are showing as below:
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-06-07), THC Therapeutics's stock price is $0.0033. THC Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jul. 2023 was $0.00. Therefore, THC Therapeutics's PS Ratio for today is .
The historical data trend for THC Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
THC Therapeutics Annual Data | |||||||||||||||||||||
Trend | Jul14 | Jul15 | Jul16 | Jul17 | Jul18 | Jul19 | Jul20 | Jul21 | Jul22 | Jul23 | |||||||||||
EV-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
THC Therapeutics Quarterly Data | ||||||||||||||||||||
Oct18 | Jan19 | Apr19 | Jul19 | Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | |
EV-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
For the Drug Manufacturers - Specialty & Generic subindustry, THC Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, THC Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where THC Therapeutics's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
THC Therapeutics's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 0.845 | / | 0 | |
= |
THC Therapeutics's current Enterprise Value is $0.85 Mil.
THC Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jul. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
THC Therapeutics (OTCPK:THCT) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
THC Therapeutics's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 0.0033 | / | 0 | |
= |
THC Therapeutics's share price for today is $0.0033.
THC Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jul. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of THC Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Hiro Tanaka | director, officer: Vice President | 3RD FLOOR, 207 REGENT STREET, LONDON X0 W1B 3HH |
Smith Adrian J R | director, officer: Chair of the Board | 119 SPRINGLINE DRIVE, VERO BEACH FL 32963 |
Jamie Mann | director, 10 percent owner, officer: CEO, CFO | 3RD FLOOR, 207 REGENT STREET, LONDON X0 W1B 3HH |
Eden Ho | director, officer: CEO | 701 XUANG MI HU ROAD, XI YUAN, FUTIAN, SHENZHEN F4 XXXXXX |
From GuruFocus
By Marketwired Marketwired • 03-26-2018
By ACCESSWIRE ACCESSWIRE • 09-10-2021
By Marketwired Marketwired • 01-05-2021
By PRNewswire PRNewswire • 04-26-2018
By PRNewswire PRNewswire • 06-25-2018
By Marketwired Marketwired • 12-11-2020
By Marketwired Marketwired • 09-17-2019
By PRNewswire PRNewswire • 09-05-2018
By PRNewswire PRNewswire • 06-14-2018
By Marketwired Marketwired • 04-12-2018
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.